Raloxifene for postmenopausal osteoporosis

Article Abstract:

Raloxifene, which is marketed by Lilly as Evista, seems effective in preventing bone loss from postmenopausal osteoporosis. A two year long trial was done with 601 postmenopausal women taking 400 to 600 mg of elemental calcium daily. Those taking raloxifene in either 30 mg, 60 mg, or 150 mg doses showed increase in bone density from 2% to 3%, depending on dosage. This seems to be slightly less effective than estrogen plus progestin, although no direct comparison was done. Raloxifene does not seem to increase risk of cancer, but long term safety and effectiveness have not yet been tested.

Evaluation, Drugs, Product/Service Evaluation, Testing, Prevention, Raloxifene, Evista (Medication)

---

The osteoporosis revolution

Article Abstract:

Research has shed light on the factors involved in osteoporosis and ways to identify those at risk. Osteoporosis is a thinning of bone that can lead to fractures. Bone mass may be genetically determined and other physiological factors may be involved. X-rays can measure bone density and bone markers formed during the metabolism of bone can also be used diagnostically. Alendronate and calcitonin are two drugs approved to treat osteoporosis, but calcium and vitamin D are also important. Diagnostic and therapeutic measures could be expensive but so is the cost of treating hip fractures.

Care and treatment, Bones, Bone density

---

Similar abstracts:

• Abstracts: Babies need their mothers beside them! Vaccinations: mothers require motivation. Fresh hope for Paraguayan mothers: illegal abortion is a major problem in Paraguay, where abortion is illegal in all circumstances, even to save the life of the mother
• Abstracts: Health promotion departments: developing a mechanism for promoting equal opportunities in career progression. Promoting active life styles: dissemination of the HEA's Happy Heart Project
• Abstracts: The perimenopausal hot flash: epidemiology, physiology, and treatment. Prostaglandin analogues: a new classification of ocular hypotensive agents used in the treatment of glaucoma
• Abstracts: Make the fines match the crimes say judges. The low-down on pay and conditions
• Abstracts: Sleep patterns in young babies. The young ones

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.